details

The Chairman of the Nobel Foundation, Carl-Henrik Heldin, visited the NCT Heidelberg on October 1. The scientist from the Department of Medical Biochemistry and Microbiology at Uppsala University in Sweden was a guest speaker at the Heidelberg Frontiers in Medicine series. He took the opportunity to exchange ideas with colleagues on the Neuenheimer Feld campus and to get to know excellent institutions. Carl-Henrik Heldin has held leading positions in the European Molecular Biology Organization (EMBO) and the European Research Council (ERC) and was a member of the Scientific Committee of the German Cancer Research Center (DKFZ) and the Scientific Advisory Board of the European Molecular Biology Laboratory (EMBL).

At the NCT Heidelberg, Carl-Henrik Heldin discussed clinical translational cancer research and innovative treatment concepts with Dirk Jäger (right), Managing Director at the NCT Heidelberg and Head of the Department of Medical Oncology at the University Hospital Heidelberg (UKHD), and Amir Abdollahi ( left), Managing Director at NCT Heidelberg and Translational Radiooncology at the Heidelberg Ion Beam Therapy Center (HIT) of the UKHD, on clinical translational cancer research and innovative treatment concepts. In addition, Dirk Jäger explained the structure and processes at NCT Heidelberg to the guest during a tour. At the end of the brief visit, Carl-Henrik Heldin received a tour of the HIT by Amir Abdollahi.

The Chairman of the Nobel Foundation, Carl-Henrik Heldin, visited the NCT Heidelberg on October 1. The scientist from the Department of Medical Biochemistry and Microbiology at Uppsala University in Sweden was a guest speaker at the Heidelberg Frontiers in Medicine series. He took the opportunity to exchange ideas with colleagues on the Neuenheimer Feld campus and to get to know excellent institutions. Carl-Henrik Heldin has held leading positions in the European Molecular Biology Organization (EMBO) and the European Research Council (ERC) and was a member of the Scientific Committee of the German Cancer Research Center (DKFZ) and the Scientific Advisory Board of the European Molecular Biology Laboratory (EMBL).

At the NCT Heidelberg, Carl-Henrik Heldin discussed clinical translational cancer research and innovative treatment concepts with Dirk Jäger (right), Managing Director at the NCT Heidelberg and Head of the Department of Medical Oncology at the University Hospital Heidelberg (UKHD), and Amir Abdollahi ( left), Managing Director at NCT Heidelberg and Translational Radiooncology at the Heidelberg Ion Beam Therapy Center (HIT) of the UKHD, on clinical translational cancer research and innovative treatment concepts. In addition, Dirk Jäger explained the structure and processes at NCT Heidelberg to the guest during a tour. At the end of the brief visit, Carl-Henrik Heldin received a tour of the HIT by Amir Abdollahi.